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1. Introduction
Despite the advances in public health during the 18th and 19th centuries and the introduc‐
tion of immunization and antibiotics in the 20th century, bacterial infection is among the
most frequently encountered and costly causes of diseases and one of the major causes of
morbidity and mortality especially in developing countries (El-Ghany et al., 2005). Localiz‐
ing and distinguishing the “infection foci” in body sites are very important and life saving
processes. The identification of an infection at early stage of disease is critical for a favorable
outcome. The diagnosis of deep seated infections such as osteomyelitis, endocarditis and in‐
tra-abdominal abscesses is still a challenging problem. Although imaging techniques such as
x-ray, computerized tomography (CT-scan), magnetic resonance imaging (MRI) and ultraso‐
nography (US) might be helpful, but none of these techniques are specific for infection diag‐
nosis because of their limitations due to insignificant anatomical changes in the early stages
of the infection process. In addition, these techniques are not capable of differentiating be‐
tween inflammatory and infectious processes. In contrast, nuclear medicine procedures can
determine the location and the degree of disease activity in infectious processes based on
physiologic and/or metabolic changes that are associated with these diseases rather than
gross changes in the structure (Hall et al., 1998). This method requires a reliable radiophar‐
maceutical that can selectively concentrate in sites of infection. Various 99mTc-labeled com‐
pounds have been developed for the scintigraphic detection of infection and sterile
inflammation in humans. Unfortunately, these radiopharmaceuticals do not discriminate be‐
tween infection and sterile inflammatory process, which is often of clinical importance
(Welling et al., 2001). In recent years, the development of radiolabeled antimicrobial agents
for specific diagnosis of infection has received considerable attention, sparking a lively de‐
bate about the infection specificity of these radiopharmaceuticals (Oyen et al., 2005). Direct
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targeting of the locally present microorganisms is a new approach for improving the selec‐
tivity of radiopharmaceuticals for infection detection in nuclear medicine (Kyprianidou et
al., 2011). The use of radiolabeled antibiotics and antimicrobial peptides are fast emerging as
promising targeted diagnostic tests for detection of infective lesions because of their specific
binding to the bacterial component. These targeting molecules reliably locate sites of infec‐
tion and make a differential diagnosis between infection and sterile inflammation. In this
chapter, the new approaches to scintigraphic imaging of infection and inflammation by radi‐
olabeled antibiotics and antimicrobial peptides are thoroughly discussed in order to assess
their diagnostic value as targeting imaging radiopharmaceuticals.
2. Inflammation and infection
Inflammation and infection are different processes. Inflammation is merely a nonspecific im‐
mune response-one which does not require the presence of microorganisms to occur. In‐
flammation can occur from trauma, ischemia, neoplasm, autoimmune attack or invasion by
microorganisms (Petruzzi et al., 2009). Infection can be considered as a special subcategory
of inflammatory disease, i.e. an inflammatory reaction of the host in response to invasion by
microorganisms (Oyen et al., 2005). All inflammatory processes develop along a known se‐
quence: locally increased blood supply, leakage of a fluid, small molecules and proteins and
infiltration of cells (Rennen et al., 2002). In response to tissue damage, powerful defense
mechanisms are activated, consisting of leukocytes and plasma proteins. Furthermore, a
complex of variety of chemical mediators is involved. The migration of leukocytes from the
blood stream is facilitated by chemical mediators which up regulated the expression of ad‐
hesion molecules on endothelial cells and leukocytes. This process starts within minutes
from the injury and resolves in hours or days. It causes the classical symptoms of acute in‐
flammation; rubor (redness), calor (warmth), tumor (edema), dolor (pain) and fastio laesa
(impaired function) (Bleeker-Rovers, 2004). The ability to identify focal sites of infection in
patients who do not present with localizing symptoms is a key step in delivering appropri‐
ate medical treatment. This is particularly critical in immune compromised patients, since
signs and symptoms of infection may be minimized in patients with neutropenia (Babich &
Fischman, 1999). There are several reasons why imaging of infection and inflammation and
distinguishing between them becomes increasingly important in the next decade. The popu‐
lation is ageing; the application of implants and transplants is increasing. The number of im‐
mune compromised patients is growing, mainly because of frequent use of
chemotherapeutic agents leading to neutropenia. Furthermore, the increased use of antibiot‐
ics leads to insensitivity for some of these pharmaceuticals (Larverman et al., 2008).
3. Types of infection
The most common infections are: (1) Pneumocystis carinii pneumonia (PCP) which, the large
number of patients receiving chemotherapy or harboring the HIV (human immunodeficien‐
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cy virus) are susceptible to opportunistic infection, (2) protozoal infections include cryto‐
sporidiosis and toxoplasmosis (abscess, encephalitis), (3) viral infections include
cytomegalovirus (retinitis, adrenalitis, lung, neurological, disseminated) and herpes viruses
(simplex and zoster), (4) fungal infections include Cryptococcos neoformans (meningitis, pneu‐
monitis, disseminated) and (5) bacterial infections (specially Stereptococcos and Haemophilus)
are being seen more frequently in children and intravenously drug users. Other bacterial in‐
fections include Listera monocytogenes, Salmonella, Nocardia and Mycobacteria both toberclusis
and avium intracellular (Roohi, 2006).
Infections can also be classified according to the type of pathogens including: (1) opportun‐
istic infections: infections caused by microbes belonging to the normal host flora and that in‐
itiate an infective process consequently to environmental changes, antimicrobial treatment,
traumas and injuries, the reduction of the host immune defenses, or the migration to a new
body-compartment, (2) exogenous infections: caused by pathogen organisms, which do not
belong to the normal flora but are transmitted to healthy hosts from a contaminated envi‐
ronment (food and water) or from infected carriers (humans or animals). The main routes of
transmission of exogenous pathogens from an infected carrier are the air and aerosol, sexual
intercourse, blood transfusions or animal bites. Exogenous infections can be classified ac‐
cording to the site of acquirement in: (1) community-acquired infections: when the transmis‐
sion occurs within the community, (2) healthcare-acquired infections: when the pathogen is
transmitted within a hospital or a health-care institution; Finally, iatrogenic infections are
those developed consequently to a medical procedure such as pharmaceutical treatment or
surgery, and could be caused either by endogenous or exogenous pathogens (Baldoni, 2009).
4. Infection diagnosis techniques
The identification of infection at early stage of the disease is critical for a favorable outcome.
Conventional methods of diagnosis, relying on examination and culture of organisms from
infected foci have continued to advance embracing new technologies and automation. De‐
spite this, these methods are still time consuming, insensitive and the results often obtain
too late to guide clinical decision making (Wareham et al., 2005). Clinicians usually use a va‐
riety of laboratory tests, clinical and radiological tests, to aid diagnosis and make a decision
(Yurt Lambrecht et al., 2008a).
4.1. Laboratory tests
Many current laboratory tests used to guide the diagnostic process rely on factors in the in‐
flammatory response: erythrocyte sedimentation rate, white-blood cell count, acute-phase
proteins and cytokines, but the tests are not specific enough to discriminate between infec‐
tion and inflammation. New techniques, especially within immunology and molecular biol‐
ogy, are yielding new insights into the discrimination of infection and inflammation (Yurt
Lambrecht et al., 2008b).




Imaging techniques can be classified as either structural or functional. Structural imaging
procedures are used to evaluate macroscopic morphological changes and implant loosening.
Differently, functional imaging procedures aim to visualize the specific accumulation of an
injected gamma-emitter radiotracer at the site of infection (Baldoni, 2009). Structural imag‐
ing methods like x-ray, US, CT-scan and MRI are based on important anatomic alterations
and the possibility of a precocious diagnosis is limited. These are not the best of methods for
the localization of infection at early stages (Diniz et al., 2005). These procedures detect the
morphologic alterations of the tissues after significant process has taken place in the infec‐
tive site leading to abscess formation (Motaleb, 2007a). The results of these techniques are
unsatisfactory in the early stages of the diseases (Shah & Khan, 2011a), while nuclear medi‐
cine images are functional and can therefore identify the infection at the early stages (Mora
et al., 2010).
4.2.1. X-ray
X-ray provides a powerful tool in medicine for mapping internal structures of the human
body. Relatively inexpensive and readily available, radiographs should routinely be the ini‐
tial imaging procedure performed in all patients suspected of having musculoskeletal infec‐
tion. But, the earliest radiographic changes of osteomyelitis are soft-tissue swelling and
blurring of adjacent fat planes, which may take several days to become apparent after the
onset of infection. Approximately 10 days after the onset of infection, radiographs may dem‐
onstrate lysis of medullary trabeculae, focal loss of cortex, and periosteal reaction The sensi‐
tivity of plain radiography ranges from 43% to 75%, and the specificity from 75% to 83%.
Though helpful when positive, a negative study does not exclude osteomyelitis (Palestro et
al., 2006). Despite its limitations, radiographs remain the best initial examination in cases of
symptomatic postoperative patients and may depict findings associated with postoperative
infection (Peterson, 2006).
4.2.2. Ultrasonography
Musculoskeletal tissues are, for the most part, accessible to examination by ultrasound, al‐
lowing its deployment as a first-line investigation in a wide range of musculoskeletal infec‐
tions. In addition, ultrasound is noninvasive, portable, and versatile. Further, it does not use
ionizing radiation, and it is relatively lower in cost. However, ultrasound images have a ma‐
jor disadvantage: poor quality because of multiplicative speckle noise that results in arti‐
facts. Segmentation of lesions in ultrasound images is therefore a challenging task that
remains an open problem despite many past research efforts (Yap et al., 2008). On the other
hand, ultrasonography is very commonly used during the initial work-ups of children with
urinary tract infection (UTI) because it gives a rapid anatomical overview of the kidneys, es‐
pecially with regard to the dilatation of the collecting system (Wu et al., 2003). The disad‐
vantages are that the results are highly operator-dependent, penetration and reflection of
the sound waves in tissue may be hindered by gas (bowel) or dense structures (bone), and
structures deep within the body may be difficult to visualize because the image quality suf‐
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fers from the longer wavelengths used for deep imaging (Gotthardt et al., 2010). UItrasonog‐
raphy is useful technique for diagnosing and localizing fluid collections, but it often cannot
determine whether a particular fluid collection is infected or not (Fortner et al., 1986).
4.2.3. Computed Tomography (CT)
CT-scan is an x-ray imaging technique that produces three dimensions (3D) images of an ob‐
ject by using a series of two-dimensional (2D) set of images data to mathematically reconstruct
a cross-section of it. CT is unique because it provides imaging of a combination of soft tissues,
bone and vessels, and many studies have confirmed CT to be a valid complement to conven‐
tional imaging methods (Cotti & Campisi, 2004). CT is highly reproducible, has an excellent
spatial resolution, and although more expensive than ultrasonography, is still relatively inex‐
pensive. The disadvantages are exposure of the patient to radiation and lack of functional in‐
formation (Gotthardt, 2010). It is also limited by a lack of specificity of many of the imaging
findings that are noted in the setting of infection or inflammation (Kumar et al., 2008).
4.2.4. Magnetic Resonance Imaging (MRI)
While MRI provides very high resolution (up to 10 μm) and unlimited depth of penetration,
it is, however, limited by low sensitivity, with detectabilities in the milli to micromolar (10-3
to 10-6) range. Therefore, amplification techniques are often needed to image molecular proc‐
esses in vivo (Bonekamp et al., 2010). Advantages of MRI are the superb anatomic details it
reveals (including the ability to evaluate both bone and adjacent soft tissue), its lack of ioniz‐
ing radiation, and its rapid completion. Disadvantages of MRI are occasional inability to dis‐
tinguish infectious from reactive inflammation, and difficulty in imaging sites with metallic
instrumentation such as joint prostheses (Palestro et al., 2006). It is also limited by a lack of
specificity of many of the imaging findings that are noted in the setting of infection or in‐
flammation (Kumar et al., 2008). Because of the long imaging times and the considerable ex‐
posure to noise, MRI is not convenient for patients. Furthermore, there are limitations to the
scanning of patients with pacemakers, implants, and other devices, and the procedure is rel‐
atively expensive (Gotthardt et al., 2010).
5. Nuclear medicine
Nuclear medicine is a highly multi-disciplinary specialty that develops and uses instrumen‐
tation and radiopharmaceuticals to study physiological processes and non-invasively diag‐
nose, treat and identifying the staging of a disease (Hricak, 2007). The radiopharmaceuticals
are molecular and cellular structures labeled with a specific radionuclide and are applied to
patients after appropriate quality control (Bernardo-Filho et al., 2008). A radiopharmaceuti‐
cal is usually made up of two components: a basic substance for localization in a desired tis‐
sue or organ, and a radionuclide for tagging to the basic substance to emit the gamma rays
that can be detected and imaged with a gamma camera. The efficacy of the radiopharma‐
ceutical is therefore determined by these components (Korkmaz & Ozer., 2006). Radiophar‐
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maceuticals localize in inflamed or infected tissue in the body. The radiopharmaceuticals
emit gamma rays that can be detected and imaged when a patient is placed in a gamma
camera (Truluck, 2007). Radionuclide emission-based nuclear medicine modality is a nonin‐
vasive technique, which is a quick, sensitive, and specific method to detect as well as locate
the lesion at any anatomical site at early stage of the disease (Singh & Bhatnagar, 2010).
5.1. Advantages of nuclear medicine technique
Nuclear medicine has an important role in adding the diagnosis of particularly deep seated
infections such as abscesses, osteomylitis, septic arthritis, endocarditis and infections of
prosthetic devices (Das et al., 2002). It provides information on pathophysiological and path‐
obiochemical processes. In this respect it differs from other current imaging procedures such
as x-ray, CT and MRI, which supply information with high resolution on the morphological
changes that occur in a specific disease. In addition, nuclear medicine technique permits
whole-body imaging, whereas CT and MRI routinely focus on just a part of the body (Becker
& Meller, 2001). Nuclear medical imaging has an important role in discriminating infections
from inflammation. Inflammatory processes can be visualized in their early phases, when
anatomical changes are not yet apparent (Yurt Lambrecht et al., 2008a). The early detection
of the infectious focus by radionuclide imaging helps both patient and physician to reduce
the cost and the length of hospitalization (El-Ghany et al., 2005).
5.2. Current radionuclides for infection imaging
The radionuclide is a substance which continuously emits the radiation. Generally this radi‐
ation consists of alpha-rays, beta-rays and gamma-rays (Patei Riddhi et al., 2011). Radio‐
pharmaceuticals can be labeled with various radionuclides such as 67Ga, 99mTc, 111In, 18F, 131I,
etc. (Oyen et al., 2001). Technetium-99m is one of the most desirable radionuclides that is
used in clinical nuclear medicine, due to the emission of gamma ray of optimal energy (140
keV), a suitable half-life (6 h), availability from 99Mo-99mTc generator systems and low cost
(Arano, 2002, & Oyen et al., 2001).
5.3. Imaging systems in nuclear medicine for infection diagnosis
Gamma camera, single photon emission tomography (SPECT) and positron emission tomog‐
raphy (PET) are current imaging systems in nuclear medicine for infection diagnosis.
5.3.1. Gamma camera
In nuclear medicine, the most common imaging systems are general-purpose systems,
which allow a wide variety of morphological and physiological studies. While dedicated x-
ray equipments for specific examinations are largely found in diagnostic radiology, this is
not the case for nuclear medicine, where general purpose gamma cameras are commonly
used (Sanchez et al., 2004). Tools like portable gamma cameras make it possible to quickly
and simply perform the gamma mapping of an area to be processed, with the advantage of
remote measurements of hot spots, not necessarily on contact. However, the use of such
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cameras on site sometimes comes up against an insufficient sensitivity or space resolution,
or against their excessive bulk (Gal et al., 2006).
5.3.2. Single photon emission tomography
Single photon emission computed tomography (SPECT) is a functional and molecular imag‐
ing modality, which is being used clinically to localize targets prior to biopsy and surgery
(Roper et al., 2012). SPECT shows function by means of a three dimensional activity distri‐
bution of a radioactive tracer, which was injected prior to the measurement (Changizi et al.,
2008). The principal values of SPECT are, as the result of the disposability of numerous sin‐
gle-photon radiopharmaceuticals, its broad clinical availability and its versatility for the ev‐
eryday management of patients affected by several different conditions. Moreover, it is able
to increase contrast and to allow better delineation of pathologies than planar imaging.
However, the main limitation of SPECT imaging is its poor anatomical information; in fact,
it yields essentially functional or molecular information that therefore are very suitable to be
integrated with imaging modalities such as CT or magnetic resonance imaging (MRI), which
provide morphological details (Schillaci et al., 2007). The hybrid SPECT/CT system delivers
the high sensitivity of scinitigraphic technology with the high specificity of CT. This reduces
the disadvantage of the SPECT’s low spatial resolution (Bruni et al., 2008).
5.3.3. Positron emission tomography
Positron emission tomography is an improving technology and it is a promising field for the
diagnosis of the diseases in relatively early stages. β+ emitting radioactive isotopes are used
in PET imaging (Silindir & Ozer, 2008). The most commonly used PET radionuclides are 11C
(half-life ≈ 20 min) and 18F (half-life ≈110 min) (Bonekamp et al., 2010). FDG (flourodeoxyglo‐
cose) has proven to be an excellent tracer to detect inflammation in the setting of either in‐
fectious or noninfectious processes. The potential of FDG-PET for detecting inflammatory
processes in disorders such as regional ileitis, sarcoidosis, rheumatologic disease, and vascu‐
litis and any other disorders is also vast (Alavi et al., 2004). The major shortcomings of this
modality include (1) limited availability in most parts of the world, (2) relatively high cost,
and (3) difficulty in differentiating malignant tissue from infection or inflammation, al‐
though delayed imaging and dual-time-point PET is of considerable help in this regard (Ba‐
su et al., 2009). A newer technique that has recently gained favor in clinical use is PET-CT
imaging for the rapid detection and localization of occult infection (Petruzzi et al., 2009).
6. Conventional nuclear medicine techniques for infection/inflammation
imaging
Conventional nuclear medicine techniques make the use of the following radiopharmaceuti‐
cals for infection/inflammation imaging: 67Ga-citrate, 99mTc or 111In-labeled leukocytes, 99mTc-
labeled granulocyte antibodies, radiolabeled chemotactic peptides, 99mTc or 111In-labeled
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human immunoglobulin (HIG), 99mTc-nanocolloids, radiolabeled liposomes, cytokines,
streptavidin-biotin and 18F-flourodeoxyglocose (18F-FDG).
6.1. 67Ga-citrate
Gallium-67 (67Ga) citrate has been used for detecting infection and inflammation ever since
its discovery in 1971 (Kuo et al., 2002). Gallium-67 is a bioisoester of ferric iron with physical
half-life of 3.3 days (78 hr) and biologic half-life of 2-3 weeks that binds to serum via trans‐
ferrin, haptoglobin, albumin and globulins. Gallium attaches to tissues mediated by lactofer‐
rin, as well as lymphocytes and macrophages (Jallilian et al., 2009). Gallium citrate is a
radiopharmaceutical used for the detection and staging of some cancers and for identifying
inflammation and infection. In the second category, typical indications for 67Ga scanning in‐
clude sarcoidosis, pneumonia, pyelonephritis, fibrosis, AIDS-related inflammations, osteo‐
myelitis, and fevers of unknown origin (Truluck, 2007). However, this radiopharmaceutical
has long physical half-life and high energy gamma radiations, which are unfavourable char‐
acteristics for gamma camera imaging and cause high radiation absorbed dose in the pa‐
tients (Malviya et al., 2007). The specificity of the technique is low, due to physiologic al
bowel excretion and accumulation in malignant tissues and areas of bone modeling (Rennen
et al., 2002).
6.2. 99mTc- or 111In-labeled leukocytes
Since the 1970s, scintigraphic imaging with labeled white blood cells has been the most fre‐
quently used nuclear imaging method for clinical diagnosis of infection and inflammation
worldwide. The success of white blood cell scintigraphy is primarily due to its superb diag‐
nostic accuracy (Signore et al., 2009). Of many radioisotopes used to label leucocytes, Indi‐
um-l11 tropolonate (111In) and Technetium-99m hexamethyl propylene amine oxime (99mTc
HMPAO) are the most widely used (Giaffer, 1996). The principal clinical indications for ra‐
diolabeled leukocytes include inflammatory bowel disease, osteomyelitis, follow-up of pa‐
tients with infections of vascular or orthopedic prostheses and soft tissue infections. There
has always been concern that chronic infections could be missed using radiolabeled leuko‐
cytes, because these infections generate a smaller granulocyte response compared to acute
infections (Larverman et al., 2008). Radiolabeled white blood cell (WBC) scintigraphy, ena‐
bles detection of areas of general inflammation but cannot be used to distinguish between
bacterial and nonbacterial inflammatory processes (Sonmezoglou et al., 2001). Although, the
radiolabeled leucocytes can be considered as ‘‘gold standard’’ that can visualize a majority
of infectious and inflammatory lesions, but it is labor-intensive and the in vitro labeling car‐
ries risks of handling potentially contaminated blood and also requires specialized equip‐
ment, taking approximately three hours (Mirshojaei et al., 2011).
6.3. 99mTc-labeled granulocyte antibodies
Ever since it became clear that labeled leukocytes could visualise infectious foci, investiga‐
tors have been developing a method that could label leukocytes in vivo (Larikka, 2003). For
in vivo labeling, immunoscintigraphy with 99mTc labeled monoclonal anti-granulocyte anti‐
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bodies (AGAb) is used (Gyork et al., 2000). The accumulation mechanism involves nonspe‐
cific related uptake of free antibody because of an increased capillary permeability at the
focus, with subsequent binding to granulocytes (Lyra et al., 1998). The first approach regard‐
ing in vivo labeling was the murine IgG1k antibody BW 250/183 (99mTc-besilesomab, Scinti‐
mun®) which recognized the nonspecific cross reacting antigen 95 (NCA-95; also referred to
as CD66b and CEACAM8) in the cytoplasm and on the cell membranes of granulocytes and
granulocyte precursor cells (Ritcher et al., 2011). Three antigranulocyte antibodies have been
tested for infection imaging: anti-NCA-95 immunoglobulin G (IgG) (BW250/183), anti-
NCA-90 Fab (Immu-MN3, Leukoscan: anti-CD66), and anti-CD15 (LeuTech). Each of these
antigranulocyte antibodies labeled with 99mTc were determined to accurately delineate infec‐
tion and inflammation. None of these compounds, however, were specific for infection only
(Petruzzi et al., 2009). Fanolesomab is a monoclonal murine M class immunoglobulin that
binds to CD15 receptors present on leukocytes. Antibody fragments are appealing because,
unlike the whole antibody, they do not induce a human antimouse antibodies (HAMA) re‐
sponse. Sulesomab is a murine monoclonal antibody fragment of the IgG1 class that binds to
normal cross-reactive antigen-90 present on leukocytes (Palestro & Love, 2009). Disadvan‐
tages of the use of monoclonal antibodies, however, are the high molecular weight, resulting
in slow diffusion into sites of inflammation, a long plasma half life and uptake in the liver
due to clearance by the reticulo-endothelial system. Use of monoclonal antibodies of murine
origin sometimes induces generation of HAMA, which can lead to allergic reactions and al‐
tered pharmacokinetics when repeated injections are given. This is, of course, a major limita‐
tion for follow-up studies (Larverman et al., 2008). Some radiolabeled mAbs (such as anti-E-
selectin and anti-CD4) demonstrated their excellent capability for the localization of
inflammatory regions, but lack of their use for the therapeutic purposes, thus limiting their
further development and (Malviya et al., 2011).
6.4. 99mTc- or 111In-labeled chemotactic peptides
Radiolabeled chemotactic peptides are promising tools for the imaging of inflammation and
infection. Chemotactic peptides are naturally released by bacteria and initiate leukocyte che‐
motaxis by binding to high-affinity receptors on the white blood cell membrane. These re‐
ceptors are present on polymorphonuclear neutrophils and monocytes (Hartwig et al., 1999).
The tripeptide, formyl-methionyl-leucyl phenylalanine (f-MLF), is a bacterial product which
the initial studies for the design of infection imaging agents focused on the conjugation of f-
MLF peptide analogs with the cyclic anhydride of DTPA and radiolabeling with 111In (Ba‐
bich et al., 2000). The results of radiolabeling of four DTPA derivatized chemotactic peptides
analogs established that they are effective agents for imaging sites of infection (Fischman et
al., 1991). Small radiolabeled synthetic peptides are currently preferred over proteins and
antibodies for imaging applications, since they present several distinct advantages over
these biomolecules. Small peptides can be readily synthesized chemically. They can with‐
stand harsher chemical conditions for modification or radiolabeling. They are less likely to
induce an immunogenic response. Their plasma clearance is more rapid, yet they often
reach a high concentration in the target tissues (Okarvi, 2001). Although 111In and 99mTc-la‐
beled chemotactic peptides accumulate at sites of infection with high target-to-background
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ratios, receptor specificity has not been completely established and a significant amount of
localization could be due to nonspecific processes, such as increased tissue permeability,
blood pool or blood flow characteristics of inflammatory lesions, or characteristics of the
peptides that are not related to For-MLF receptor binding (Babich et al., 1997). However,
their development as radiopharmaceuticals has been curtailed because they cause signifi‐
cant leucopenia at physiological concentration (Das et al., 2002).
6.5. 99mTc- or 111In-labeled Human Immunoglobulin (HIG)
Investigations with monoclonal antibodies by the research group of Rubin et al. led to the
discovery of the usefulness of In-IgG scintigraphy for imaging infectious and inflammatory
foci (Oyen et al., 1992). Nonspecific polyclonal human immunoglobulins have been shown
to localize to sites of infection/inflammation by extravasations from the bloodstream due to
the induced local hyperemia and this agent is, thus, nonspecific for infection (Petruzzi et al.,
2009). 111In or 99mTc-labeled HIG has been extensively tested in a large number of clinical
studies. It has shown excellent performance in the localization of musculoskeletal infection
and inflammation, in pulmonary infection, particularly in immunocompromised patients
and abdominal Inflammation. Poor sensitivity of radiolabeled HIG is found in the diagnosis
of endocarditis and vascular lesions in general, due to long lasting high levels of circulating
activity. A general limitation is the long time span between injection and final diagnosis
(24-48 h) (Rennen et al., 2002).
6.6. 99mTc-nanocolloids
Nanocolloids are colloids of human serum albumin (HAS) less than 50 nm in size, which lo‐
calize at sites of inflammatory foci through increased capillary permeability (Das et al.,
2002). Nanocolloids are good carriers for drugs or radionuclides, the latter can be used for
diagnosis or for therapy. Radiolabeled nanocolloids have been widely used in diagnostic
nuclear medicine (Lin et al., 2003). Uptake of the tracer is presumably caused by extravasa‐
tion through the capillary basement membrane, followed by phagocytosis or adsorption of
the particles by granulocytes and macrophages (Palestro & Love, 2009). 99mTc labeled nano‐
colloids have been most commonly used for marrow and lymphatic imaging and for patient
with musculoskeletal infection. The greatest disadvantage is their inability to image infec‐
tions outside the musculoskeletal system and, as with most of the currently available radio‐
pharmaceuticals, distinguishing infection from inflammation (Das et al., 2002).
6.7. Radiolabeled liposomes
Liposomes are small vesicles consisting of one or more concentric lipid bilayers enclosing
discrete aqueous spaces. Liposomes are formed spontaneously when (phospho) lipids are
suspended in aqueous media (Larverman et al., 1999). Liposomes have been extensively
used as potential delivery systems for a variety of compounds primarily due to their high
degree of biocompatibility and the enormous diversity of structures and compositions (Mu‐
famadi et al., 2011). A formulation of liposomes, which is capable of being labeled by both
99mTc and 111In, simultaneously would have many advantages. This formulation would ena‐
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ble the acquisition of good early images in the 99mTc window of the gamma camera and ac‐
ceptable delayed images in the 111In window (Awasthi et al., 1998). Preliminary studies have
shown uptake in sterile and non sterile inflammation (Turpin & Lambert, 2001). Liposomes
continue to be very promising carriers for delivery of drugs to inflamed regions of the body,
although, to date, no clinical products have specifically taken advantage of the inflammato‐
ry targeting of liposomes (Phillips et al., 2009).
6.8. Cytokines
Cytokines are proteins and glicoproteins, members of a family of overlapping and interde‐
pendent molecules with important roles in the homeostatic control of the immune system
and of pathophysiology of different organs (Signore et al., 2000). Cytokine receptors, usually
of high affinity, are normally present at low levels on non-activated cells, but expression is
up-regulated during the cell activation and therefore these receptors on the affected tissue
are suitable targets for the detection of infection/inflammation (Malviya et al., 2007). Labeled
cytokines such as interleukin-1, interleukin-2 and interleukin-8 are a promising class of pro‐
tein radiopharmaceuticals of small molecular weight (<20 kDa) (Rennen et al., 2001). IL-1,
IL-1ra, IL-2, IL-6, IL-8, IL-10, IL-12, p40, interferon γ IFN-γ and epidermal growth factor
(EGF) have been radiolabeled for in vivo targetting of different leukocyte subsets with prom‐
ising results for their clinical use. Radiolabeled cytokines, therefore, have the potential for
use in the study of the pathophysiology of several diseases and have been used for the diag‐
nosis of inflammation and tumours (Signore et al., 2000). Cytokines and receptor antagonists
are specific for inflammation but not for infection (Das et al., 2002).
6.9. Streptavidin-biotin
The biotin-straptavidin system has been used for many years in a varity of different applica‐
tions (Diamandis & Christopoulos, 1991). Streptavidin is a protein extracted from the bacteri‐
um Streptomyces avidinii with a molecular weight of 60 kDa and has four binding sites with high
affinity (KD =10-15 M) for biotin, which is a water soluble vitamin with a molecular weight of 244
kDa (Kittigul et al., 1998). Avidin/indium-111 biotin scintigraphy is based on the non-specific
accumulation of avidin at sites of inflammation or infection, linked to increased transcapillary
leakage of macromolecules and to interstitial oedema at these sites. Due to its extremely high
affinity for and low dissociation constant with biotin, sites of infection can be imaged using avi‐
din as a pre-target, followed by 111In-labeled biotin (Lazzeri et al., 1999). The potential of radio‐
labeled biotin as an infection imaging agent has already been shown in an experimental animal
model of infection using biotin labeled with fluorine-18 as well as in a small group of patients
with osteomyelitis using 111In-labeled biotin (Lazzeri et al., 2008). Because, the mechanism of
localization is nonspecifically, based on the increasing vascular permeability, this radiophar‐
maceutical is not specific for infection imaging.
6.10. 18F-flourodeoxyglocose (18F-FDG)
A number of positron emitting radioisotopes are available for clinical use but the one most
commonly used is 18 Fluorine fluorodeoxyglucose. FDG is an analogue of glucose which
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concentrates in areas of high glycolytic activity such as rapidly dividing cells. Neutrophils
and macrophages have increased FDG uptake allowing localization of infection and inflam‐
mation (Robinson & Scarsbrook, 2009). PET with fluorine-18 fluorodeoxyglucose is a power‐
ful molecular imaging technique that allows areas with different pathologies such as
malignant neoplasias and active inflammation in clinical human studies to be assessed
(Wyss et al., 2004). Numerous reports have demonstrated increased FDG uptake at the sites
of infection and inflammation. FDG-PET is very helpful in the evaluation of chronic osteo‐
myelitis, sarcoidosis, fever of unknown origin (FUO), and differentiating toxoplasmosis
from lymphoma in the central nervous system in HIV-positive patients. Despite all of these
findings, however, FDG-PET has not been fully accepted as an effective way to evaluate in‐
fection and inflammation (Zhuang et al., 2005). This is nonspecific since 18F-FDG is also tak‐
en up at non-specific sites of inflammation as well as sites of tumor (Petruzzi et al., 2009).
7. Properties of an ideal infection imaging agent
The ideal radiopharmaceutical should enable early diagnostic imaging, a low absorbed radi‐
ation dose and make a distinction between inflammation and infection, which is of para‐
mount importance in the field of various infections including musculoskeletal, soft-tissue
and parenchymal infections. Furthermore, it should be nontoxic, inexpensive, readily availa‐
ble, and rapidly cleared from the blood and the body (Gemmel et al., 2009). The preparation
of the radiopharmaceutical should be quick and easy, preferably with technetium-99m as
the radionuclide (Larverman et al., 2008). Low levels of accumulation in bowel and blood
pool are particularly important characteristics of such an agent. Focal accumulation or tran‐
sient activity in the bowel would make detection of infections in this area very difficult. Sim‐
ilarly, high blood pool activity increases background and complicates the imaging of
vascular infections (Babich & Fischman, 1999). These properties for an ideal infection imag‐
ing agent are shown in Table 1 (Gemmel et al., 2009).
1. Rapid localization and good retention at the site of infection
2. Rapid clearance from non infected tissues (high target to background ratio)
3. Uptake in infection not in sterile inflammation, identifyingbacterial, viral and fungal infections.
4. The uptake of radiotracer should be proportional to the degree of infection. Therapy response can be monitored.
5. No pharmacological effect/immunological response, saferepeated injection.
6. Labeling should be simple and uncomplicated and wellcharacterized
7. 99mTc labeling is preferable, positron labeling is still experimental
8. Not depending on host leukocyte function
9. Less expensive than other combined modalities
Table 1. The requirements for an ideal radiopharmaceutical for infection imaging
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Considering these criteria for an ideal radiopharmaceutical for infection imaging, the best
techniques which fit this criteria better, are following by next topic.
8. Targeting nuclear medicine techniques in microorganisms imaging
The theoretical advantage of using an antimicrobial agent as the localizing agent for infec‐
tive foci is the selective toxicity of the compound for microbes rather than human targets.
Such agents should therefore be able to distinguish between inflammation due to infection
with microbial pathogens, and inflammation due to immune activity i.e. autoimmune dis‐
ease where microbes are not involved (Wareham et al., 2005). There is now a wide range of
radiolabeled antimicrobial agents that are undergoing evaluation. The first group consists of
radiolabeled antibiotics such as 99mTc- or 18F-ciprofloxacin, 99mTc-sparfloxacin, 99mTc-cefti‐
zoxime and anti-fungal agents such as 99mTc-fluconazole and 99mTc-isoniazid and the anti-
Mycobacterium tuberculosis agent 99mTc-ethambutol. The second group of
radiopharmaceuticals for imaging infections is derived from the array of human antimicro‐
bial peptides/proteins that binds to specific bacterial antigens, e.g. peptides derived from
human lactoferrin, ubiciquidin and human neutrophil peptide 1–3 (99mTc-HNP1–3; members
of the α-defensins) (Signore et al., 2008).
8.1. Antibiotics
In 1945, Selman Waksman proposed that the word antibiotic can be defined as ‘‘a chemical
substance of microbial origin that possesses antibiotic powers’’ (Davies, 2006). Antibiotics
are drugs of natural or synthetic origin that have the capacity to kill or inhibit the growth of
micro-organisms. Antibiotics are sufficiently non-toxic to the host are used as chemothera‐
peutic agents in the treatment of infectious diseases of humans, animals and plants (Hernan‐
dez Serrano, 2005). Antibiotics are designed to support host defense in controlling infection
(Kristian et al., 2007). Most antibiotics used in human treatment were originated from natu‐
ral templates produced by particular species of bacteria or fungi as a mechanism of competi‐
tion to ensure their own survival (e.g., to gain a larger share of environmental food supplies
by killing competitors (Hancock, 2005).
8.1.1. Types of antibiotics
Antimicrobial drugs are classified according to their mechanism of action, for example, cell
wall inhibiting, cell membrane inhibiting, protein synthesis inhibiting and nucleic acid in‐
hibiting (Riaz et al., 2011). The major targets for the main classes of antibiotics include cell
membranes (e.g., mupirocin), cell-wall biosynthesis enzymes and substrates (e.g., beta-lac‐
tams, vancomycin, and bacitracin), bacterial protein synthesis (e.g., chloramphenicol, tetra‐
cyclines, macrolides, clindamycin, aminoglycosides, linezolid, mupirocin, and fusidic acid),
and bacterial nucleic acid replication and repair (e.g., co-trimoxazole [trimethoprim/sulfa‐
methoxazole], which acts via an anti-metabolite mechanism, rifampicin, and quinolones)
(Hancock, 2005).
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8.1.2. Mechanisms of antibiotics action
Antibiotics interfere with the growth of bacteria by undermining the integrity of their cell
wall or by interfering with bacterial protein synthesis or common metabolic pathways. The
terms bactericidal and bacteriostatic are broad categorizations, and may not apply for a giv‐
en agent against all organisms, with certain antimicrobials being bactericidal for one bacteri‐
al pathogen but bacteriostatic for another (Niederman, 2009). Bacteriostatic agents inhibit
the growth of bacterial cells but do not kill them, whereas bactericidal agents kill the bacte‐
ria. However, these categories are not absolute, since the killing effect of the drug varies
with the test method and the species being tested. Agents may be bactericidal against one
group of organisms and bacteriostatic against another) (French, 2006). Bactericidal antibiot‐
ics, such as the beta-lactams (including the cephalosporins, carbapenems, and cephems),
glycopeptides (including vancomycin), fluoroquinolones, polymyxins, and the lipopeptide
daptomycin, are often preferred for treatment of these diseases, particularly for cases of fe‐
brile neutropenia, meningitis, and endocarditis (Hancock, 2005). The importance of bacteri‐
cidal drugs versus bacteriostatic drugs in the treatment of infections has been debated for
many years. Although the advantages of bactericidal agents appear obvious (e.g., rapid
elimination of bacteria and a decreased possibility of resistance development or infection re‐
currence), bactericidal activity could be undesirable in some clinical settings. In CNS (central
nervous system) infection, for example, the sudden lysis of bacteria by a bactericidal agent
leads to a sudden increase in bacterial products (e.g., lipopolysaccharide in gram-negative
organisms or peptidoglycans in gram-positive organisms) that may stimulate cytokine pro‐
duction, causing potentially harmful inflammation (Finberg et al., 2004).
8.1.3. Review on radiolabeled antibiotics
Agents that specifically target the infectious organisms (e.g., bacteria, fungi or viruses) have
potential to distinguish microbial from non microbial inflammation (Boerman & Nijmegen,
2008). The first and most intensively studied agent in this category is 99mTc-ciprofloxacin
(99mTc-infecton), a member of fluoroquinolone group that was introduced by Solanki et al. as
a new class of radiopharmaceutical for infection imaging in 1993 (Solanki et al., 1993). The
results of 99mTc-infecton clinical application in imaging patients with various infections are
shown in Table 2.
Moreover, radiolabeling of some other quinolone antibiotics, cephalosporines, antifungal
agents, anti mycobacterium tuberculosis and also antiviral radiopharmaceuticals for targeting
diagnosis of infectious foci, were investigated up to now.
8.1.3.1. Radiolabeled antibacterial agents
The use of radiolabeled antibiotics is fast emerging as a promising diagnostic test for the de‐
tection of infective lesions, because of their specific binding to the bacterial component
(Singh et al., 2005). The first clinical application of 99mTc-ciprofloxacin was performed by
Vinjamuri et al. in 1996 and the ability of 99mTc infecton imaging in comparison with radiola‐
beled white blood cell imaging for evaluating of bacterial infection, were investigated (Vin‐
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jamuri et al., 1996). The results showed 84% sensitivity and 96% specificity of 99mTc
ciprofloxacin in contrast to 81% sensitivity and 77% specificity of white blood cell imaging.
Ciprofloxacin has several advantages over radiolabeled leucocytes, and other methods for
imaging infection, which include the following: (1) specificity for infection, (2) lack of bone
marrow uptake, which is a significant advantage in imaging bone and joint and orthopedic
prostheses infections, (3) ease and cost of preparation of the agent, (4) ex vivo labeling, which
avoids contact with blood and hence the risk of acquiring blood borne infections such as
HIV and hepatitis B and C, (5) independence of the host inflammatory response and neutro‐
phil count and hence it can be used to image infections in immunocompromised patients,
including those who are neutropaenic, where culture is often negative and white blood cell
imaging unreliable and (6) availability in a kit format with long shelf-life, making it user
friendly and more widely available (Akhtar et al., 2012). However, the low binding affinity
of 99mTc-ciprofloxacin to bacteria and the risk of emerging antibiotic-resistant microorgan‐
isms make this radiopharmaceutical unattractive for imaging bacterial infections (Welling et
Type of infection Number ofpatients Sensitivity (%) Specificity (%) Reference
Known or suspected sites of
infection 56 84 96 Vinjamuri et al., 1996
Various infections with proven
microbiological tests 99 83 91 Britton et al., 1997
Suspected of a variety of
infections 90 70.3 93.1 Hall et al., 1998
Suspected orthopaedic infection 15 85 92 Yapar et al., 2001
Clinically suspected





879 (in 8 country
under the auspices
of the IAEA)
85.4 81.7 Britton et al., 2002
Proven or suspected bone
infection 45 97.2 80 Malamitsi et al., 2003
Suspected septic arthritis or
osteomyelitis 27 100 37.5 Sarda et al., 2003
Postoperative spinal infection 48 52 79 De Winter, et al., 2004
Acute or chronic
cholecystitis based on the clinical
and ultrasonographic
findings
60 91.7 75 Cho et al., 2007
Table 2. Some reported clinical applications of 99mTc-ciprofloxacin (infecton).
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al., 1999). The majority of other fluoroquinolone antibiotics, some of the cephalosporins and
also other antibacterial agents were radiolabeled up to now for bacterial infection imaging
with promising results (Table 3).







Ceftizoxime Cephalosporine- thirdgeneration Tc-99m Escherichia coli 3.24
Gomes Barreto et al.,
2000, 2005
Floclunazol Antifungal Tc-99m Candida albicans-Aspergillus fumigates 3.6 Lupetti et al., 2002
Isoniazid Antituberclosis Tc-99m Mycobacteriumtuberculosis - Singh et al., 2003
Enrofloxacin Fluoroquinolone-second generation Tc-99m
Staphylococcos aureus and
Candida albicans 4.25 Siaens et al., 2004
Vancomycin Glycopeptide antibiotic Tc-99m Staphylococcos aureus25923 5 Roohi et al., 2005
Pefloxacin Fluoroquinolone-second generation Tc-99m Escherichia coli 5.6 El Ghany et al., 2005
Ethambutol Antituberclosis Tc-99m Mycobacteriumtuberculosis - Verma et al., 2005
Kanamycin Aminoglycoside Tc-99m Staphylococcos aureus25923 2.5 Roohi et al., 2006
Cefoperazone Cephalosporin-forthgeneration Tc-99m Staphylococcus aureus 4.5 Motaleb, 2007a
Lomefloxacin Fluoroquinolone-second generation Tc-99m Staphylococcus aureus 6.5 Motaleb, 2007b
Ofloxacin Fluoroquinolone-second generation Tc-99m Staphylococcus aureus 4.3 Motaleb, 2007b
Sparafloxacin Fluoroquinolone-third generation Tc-99m Staphylococcus aureus 5.9 Motaleb, 2009
Cefuroxime axetil Cephalosporin-secondgeneration Tc-99m Staphylococcus aureus 2.5
Yurt Lmbrecht et al.,
2008a
Linezolid Oxazolidinone I-131 Staphylococcus aureus 5.5 Yurt Lmbrecht et al.,2009
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Moxifloxacin Fluoroquinolone-forthgeneration Tc-99m Escherichia coli 6.8
Chattopadhyay et al.,
2010
Norfloxacin Fluoroquinolone-second generation Tc-99m Staphylococcus aureus 6.9 Ibrahim et al., 2010
Rifampicin Rifamycin group Tc-99m Methicillin-resistantStaphylococcus aureus 7.34 Shah et al., 2010
Ceftriaxone Cephalosporin- thirdgeneration Tc-99m Escherichia coli 5.6 Mostafa et al., 2010
Gemifloxacin Fluoroquinolone-forthgeneration Tc-99m Streptococcus pneumoniae 4.88 Shah & Khan, 2011a
Rufloxacin Fluoroquinolone-second generation Tc-99m Staphylococcus aureus 6.04 Shah & Khan, 2011b
Clinafloxacin Fluoroquinolone-forthgeneration Tc-99m Staphylococcus aureus 4.96 Shah & Khan, 2011c








5.4 Shah et al., 2011b
Cefotaxime Cephalosporin- thirdgeneration Tc-99m Staphylococcus aureus 2.98 Mirshojaei et al., 2011
Gatifloxacin Fluoroquinolone-forthgeneration Tc-99m Escherichia coli 4.5 Motaleb et al., 2011
Cefepime Cephalosporin- forthgeneration Tc-99m Escherichia coli 8.4 Motaleb et al., 2011
Levofloxacin Fluoroquinolone-third generation Tc-99m Staphylococcus aureus 17.2 Naqvi et al., 2012
Table 3. The history of radiolabeled antibiotics applied in infection imaging.
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8.1.3.2. Radiolabeled antituberculous agents
Mycobacterial infections have been shown to be increasing in number worldwide, mainly due
to a global increase in developing countries, the increased number of patients with HIV infec‐
tion and AIDS disease worldwide, an increasing the number of elderly patients and the emer‐
gence of multidrug resistant tuberculosis (De Backer et al., 2006). Tuberculosis is an ancient
infectious disease that remains a threat for public health around the world. Although the etio‐
logical agent as well as tuberculosis pathogenesis is well known, the molecular mechanisms
underlying the host defense to the bacilli remain elusive (Jordao & Vieira, 2011). A suitable li‐
gand, ethambutol (EMB) that is, specific first line antitubercular drug was chosen for detection
as well as localization of the lesion using nuclear medicine modality. 99mTc-EMB was used in
humans for tubercular imaging. The mycobacterial lesion uptake study carried out so far in hu‐
mans suggested that 99mTc-EMB is specific and sensitive radiopharmaceutical for sensitive as
well as resistant tubercular lesion detection and localization (Singh & Batnagar, 2010). Isonia‐
zid is another antituberculous agent that binds to mycolic acid in the cell walls of living myco‐
bacteria.  Successful  imaging  of  Mycobacterium  tuberculosis  cold  abscesses  in  rabbits  was
reported along with rapid washout from Staphylococcos aureus infected abcesses suggesting the
agent my be very useful for the detection and follow up of tuberculous lesions in humans
(Wareham et al., 2005). Ethambutol was successfully labeled with 99mTc followed by studies on
mice and rabbits for labeling efficiency, in vitro and in vivo stability, blood kinetics, and organ
distribution (Table 3). Therefore it was concluded that this radiolabeled agent can be used for
detection and follow up of tuberculous lesions in patients especially to determine the treat‐
ment endpoint of antituberculous drugs (Akhtar et al., 2012).
8.1.3.3. Radiolabeled antifungal agents
During the past two decades, invasive fungal infections have emerged as a major threat to im‐
munocompromised hosts. Patients with neoplastic diseases are at significant risk for such in‐
fections as a result of their underlying illness and its therapy (Shoham & Levitz, 2005). Candida
albicans is the most common fungal pathogen, and is the organism responsible for the majority
of localized fungal infections in humans (De Assis et al., 2008). Fluconazole is the most fre‐
quently employed among the triazole antifungal agents in treating Candida infections in indi‐
viduals with severe immunodeficiency (Lupetti et al., 2011). It was successfully labeled with
99mTc by Lupetti et al., in 2002. This labeled compound successfully detected infections with
Candida albicans but not bacterial infections or sterile inflammatory sites in animals (Table 3)
(Lupetti et al., 2002). In the attempt to develop new tracers that specifically detect fungal infec‐
tions, components of fungal cell wall have been considered highly selective targets. Since chi‐
tin is a component of fungal cell wall, which is absent in mammalian cells, a radiolabeled
marker for chitine, 123I-chitinase was developed in order to bind specifically to fungal cells (Lu‐
petti et al., 2011). It was tested for specificity in a mouse model to localize fungal infections with
both Candida and Aspergillus species. Furthermore, the chitinase uptake appeared to correlate
well with the number of viable fungal cells (Gemmel et al., 2009). The results revealed that this
radioiodine labeled enzyme accumulates in Candida albicans and Aspergillus fumigatus infec‐
tions in mice; these infections can be visualized at 24 h after injection of the tracer and its accu‐
mulation,  correlates with the number of  viable fungal  cells  without visualizing bacterial
infections or sterile inflammations (Lupetti et al., 2011).
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8.1.3.4. Radiolabeled antiviral agents
Antiviral therapeutics deals specifically with the treatment of viral infections and refers to
the use of drugs and the methods of the execution in the treatment of life-threatening viral
diseases (Saxena et al., 2009). Development of a suitable radiolabeled antiviral drug probe
must take into account the specificity of metabolism of the drug by virus-infected cells, the
capability and convenience of labeling the drug without altering that specificity, and the bio‐
distribution of the drug (Price et al., 1983). The possibility of using a naturally occurring vi‐
rus-encoded molecule as an imaging reporter was first explored in the early 1980s, when
acyclovir was approved as an antiviral drug for the treatment of HSV (herpes simplex virus)
infections. The ability of this and other nucleoside analogues to selectively inhibit HSV repli‐
cation is based on their ability to undergo phosphorylation by the viral thymidine kinase
(TK), but not by corresponding host enzymes (Bray et al., 2010). Ideally, the drug to be used
should be phosphorylated exclusively by viral TK and, therefore, label only infected cells
(Price et al., 1983). Among various substrates, radiolabeled 2′-fluoro-2′-deoxy-5-iodo-1-β-D-
arabinofuranosyluracil (FIAU) demonstrated high sensitivity and selectivity for the detec‐
tion of HSV1-tk expression. FIAU is trapped intracellularly only in the presence of HSV1-tk
(Bengel et al., 2000). Another antiviral drug, 2'-fluoro-5-methyl-1-beta-D-arabinosyluracil la‐
beled with carbon 14 ([14C]FMAU), was used as a probe for selectively imaging brain infec‐
tion in a rat model to diagnosis of herpes simplex encephalitis by quantitative
autoradiography (Saito et al., 1984). Stavudine, 2′, 3′ didehydro-3′-deoxythymidine (d4T), is
a synthetic thymidine nucleoside analog that is effective in the treatment of human immu‐
nodeficiency virus (HIV) infection. Stavudine enters cells rapidly by nonfacilitated diffusion,
with the rate of influx being linear with respect to concentration. This potent antiviral agent
was radiolabeled with 11C and the results showed that future PET studies with this radio‐
pharmaceutical will allow in vivo measurements of the pharmacokinetics of stavudine in
both animal models and human subjects (Livni et al., 2004). The replication cycles of various
DNA and RNA viruses offer a variety of targets for drugs and probes that interact specifical‐
ly with virus-encoded molecules which made candidate tracers of different virus families
for virus-specific imaging (Bray et al., 2010).
8.2. Antimicrobial peptides
Antimicrobial peptides are widespread in living organisms constitute an important compo‐
nent of innate immunity to microbial infections. By the early 1980s, more than 800 different
antimicrobial peptides had been isolated from mammals, amphibians, fish, insects, plants
and bacterial species. In humans, they are produced by granulocytes, macrophages and
most epithelial and endothelial cells (Kamysz, 2005). Antimicrobial peptides usually contain
hydrophobic and cationic amino acids, which are able to organize in an amphipatic struc‐
ture (Lupetti et al., 2003a). They can be expressed constitutively or induced during inflam‐
mation or microbial challenge. Antimicrobial peptides displayed antibacterial, antiviral and
antifungal activities in vitro and were effective in experimental infections with multidrug re‐
sistant Staphylococcus aureus and Mycobacterium tuberculosis (Lupetti et al., 2003b). Due to the
development of microorganisms' resistant to the most widely used antibiotics and antifun‐
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gal agents, antimicrobial peptides have gained renewed attention as possible therapeutic
candidates (Lupetti et al., 2003c). Difficulties arising in purifying natural antimicrobial pepti‐
des from various sources have prompted the recombinant production of antimicrobial pepti‐
des by genetically engineered bacteria or by peptide synthesis. Such methods result in
sufficient amounts of antimicrobial peptides produced under good laboratory practice con‐
ditions, which is essential for future approval to use the peptides in clinical trials. Peptide
synthesis also allows the production of chemical variants, such as denantiomers, peptides
that have amino acid substitutions at various positions, and peptide libraries (Lupetti et al.,
2003b). Synthetic peptides are usually small, rapidly removed from the circulation and other
body compartments, and flexible, because they do not hold a particular structure in a hydro‐
philic environment, and display a favorable adverse effect profile (Akhtar et al., 2012).
8.2.1. Types of antimicrobial peptides
Antimicrobial peptides usually contain less than 50 amino acids with a net positive charge due
to an excess of basic residues, such as lysine and arginine, and approximately 50% hydropho‐
bic amino acid (Lupetti et al., 2003c). According to combination of sequence homologies, three
dimensional structures and functional similarities classification, antimicrobial peptides can be
divided into 5 main classes: (1) linear, mostly α-helical peptides without cysteine residue, with
or without hinge region (bombinins, cecropins, magainins), (2) antimicrobial peptides with
one disulfide bond that form a loop structure with a tail (bactenecins, esculentins), (3) antimi‐
crobial peptides with two or more disulfide bonds giving mainly or only β-sheet structure (de‐
fensins,  protegrins),  (4)  linear  peptides  without  cysteine  residue  and  with  an  unusual
composition of regular amino acids (histatins, indolicidin, temporins) and (5) antimicrobial
peptides derived from larger peptides or proteins with other known functions (lactoferricins,
MUC7). Despite differences in structure, all the peptides display a similar motif: an amphiphil‐
ic structure, with one surface being highly positive and the other hydrophobic (Kamysz, 2005).
Ubiquicidin 29-41 (UBI) is a fragment of the cationic antimicrobial peptide that is present in
various species including humans (Melendez-Alafort et al., 2003). Short peptides from lacto‐
ferrin (a 692-amino acid iron-binding protein found in body fluids, secretary granules of neu‐
trophils and mucosal epithelium), consist of HLF (human lactoferrin peptide) 1-11 and 2-11,
were tested for their ability to target infections (Knight, 2003). One of the best-studied antimi‐
crobial peptides is human neutrophil peptide (HNP)-1, which is a member of the family of de‐
fensins. This antimicrobial peptide, which is stored in the granules of human neutrophils,
contributes to bacterial killing during phagocytosis. HNP-1 displays antimicrobial activity
against gram-positive and gram-negative bacteria, many fungi and some enveloped viruses
(Welling et al., 1999). Bacteriocins are ribosomally synthetized antimicrobial peptides pro‐
duced by bacteria (Oscariz & Pisabarra, 2001). Bacteriocins are peptides secreted by cells to in‐
hibit or kill closely related species. They are divided into two basic types. The first group
comprises peptides which have been subjected to post-translatory treatment (modified bacter‐
iocins-lantibiotics). The second group includes unmodified bacteriocins. Furthermore, bacter‐
iocins comprise colicins and microcins, i.e. peptides produced by Gram-negative bacteria (e.g.,
Escherichia coli) (Kamysz, 2005).
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8.2.2. Mechanisms of antibacterial peptides action
Although the exact mechanism of action of antimicrobial peptides (AMPs) remains a matter of
controversy, there is a consensus that these peptides selectively disrupt the cell membranes
and the amphipathic structural arrangement of the peptides is believed to play an important
role in this mechanism (Peddy et al., 2004). Based on the available data, all proposed modes of
action have implicated the cationic and hydrophobic nature of the AMPs in its initial interac‐
tion with the negatively charged lipids in bacterial membranes while some variations are ex‐
pected  in  non-bacterial  targets.  Due  to  their  cationic  nature,  AMPs  are  electrostatically
attracted to negatively charge microbial surfaces such as lipopolysaccharide (LPS) in Gram-
negative bacteria and teichoic and teichuronic acids in Gram-positive bacteria (Rotem & Mor,
2009). Insertion of the peptides into the bacterial cytoplasmic membrane under the influence of
the transmembrane electrical potential gradient results in transient permeability of mem‐
branes and leakage of cellular constituents, such as potassium ions, thus destroying the pro‐
ton gradient across the membrane, resulting in bacterial cell death (Lupetti et al., 2003c).
8.2.3. Review on radiolabeled antibacterial peptides
Because antimicrobial peptides preferentially bind to bacterial membranes, radiolabeling of
these peptides would offer the medical community the novel candidates for the develop‐
ment of bacteria-seeking radiopharmaceuticals (Welling et al., 1999). A number of radiola‐
beled peptides have been evaluated for the scintigraphic detection of infections (Table 4).
Among the most specific ones are technetium-99m labeled cationic antimicrobial peptides
derived from ubiquicidin (UBI) that preferentially bind to microorganisms (Welling et al.,
2004). 99mTc-labeled ubiquicidin 29-41 (99mTc-UBI 29-41) is a highly sensitive and specific
agent for the scintigraphic detection of bacterial and fungal infections in animals and hu‐
mans. 99mTc-UBI 29-41 allows rapid visualization of Gram-positive and Gram-negative bac‐
terial infections with little or no accumulation in sterile inflammatory processes, indicating
that this peptide directly tags the microorganisms at the site of infection (Vallejo et al., 2008).
Tc-99m labeled antimicrobial peptides UBI 29-41, UBI 18-35, UBI 31-38, hLF 1-11, and defen‐
sins accumulate significantly in tissues infected with Gram-positive and Gram-negative bac‐
teria and Candida albicans. Significantly lower accumulation of these peptides occurs in
sterile inflamed tissues (Fard-Esfahani et al., 2010). The peptides hLF 1-11 and 2-11, when
labeled with 99mTc by a direct reduction technique, bound well to bacterial cells in vitro. Un‐
like 99mTc-UBI peptides, however, the labeled hLF peptides also bound to human leukocytes.
This makes them less useful for infection imaging, because they cannot adequately discrimi‐
nate between bacterial infection and sterile inflammation. Furthermore, the peptides had a
relatively high degree of hepatobiliary clearance (Knight, 2003). There are limitations attrib‐
uted to synthesis/isolation of antimicrobial peptides, labeling with isotopes, minimum de‐
tection limit of 103 Colony-Forming Unit (CFU) of bacteria, and inability to distinguish
between bacterial and fungal infections. In addition, different bacterial types reveal different
tracer accumulation (Staphylococcus aureus versus Escherichia coli). Currently no evidence re‐
garding resistance against antimicrobial peptides has been reported. Considering the merits
and demerits of radiolabeled peptides and radiolabeled antibiotics, it can currently be con‐
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cluded that radiolabeled peptides are better specific infection localizing agents than radiola‐
beled antibiotics (Akhtar et al., 2012).
Antimicrobial Peptides Radionuclide Microorganisms Experimentalmodel Reference
Human neutrophil
peptide (HNP) -1 Tc-99m
Staphylococcus aureus

































(in a kit formulation) Tc-99m
Staphylococcus aureus
-Escherichia coli Rabbits Akhtar et al., 2004










Akhtar et al., 2005
























Table 4. Some reported applications of antimicrobial peptides as infection imaging agents.
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9. Antibiotics and antimicrobial peptides radiolabeling
A simple, efficient and reproducible radiolabeling procedure is essential to develop radio‐
pharmaceuticals for routine clinical use (Gandomkar et al., 2009). The various methods of
radiolabeling with 99mTc, including the direct labeling methods for antibiotics and peptides
and indirect labeling of peptides using the bifunctional chelating agents have been dis‐
cussed. The radionuclide should be firmly attached or incorporated into the peptide to allow
the visualization of the target and reliable assessment of its pharmacokinetics after its intra‐
venous administration. Moreover, the labeling conditions should not affect the binding ac‐
tivity of the peptide to the microorganism (Lupetti et al., 2003c).
Quality assurance is the sum of all parameters concerning the preparation and control of a
finished product. Biological quality control of pharmaceutical products becomes essential as
they are ultimately to be consumed by living organisms, in particular the humans (Patei
Riddhi et al., 2011). Radiochemical purity and labeling efficiency analyses techniques are
performed by high performance liquid chromatography (HPLC), C18-Sep-pak, instant thin
layer chromatography (ITLC) and paper chromatography (IAEA-TECDOC-1414, 2004). Op‐
timum condition of labeling are required for maximum labeling of 99mTc-conjugates by opti‐
mizing the affecting factors on radiolabeling such as: pH, the amount of reducing agent and
incubation time of reaction mixture. Moreover, the stability of radiolabeled complex in hu‐
man blood serum and room temperature are determined. The biodistribution study of la‐
beled complex is done by percent uptake calculation of the tracer at various organs of
experimental animal, after intravenous administration of the radiopharmaceutical at differ‐
ent intervals to monitor the distribution style of radio complex at different organs, localiza‐
tion and high uptake at target site without any accumulation in vital organs.
9.1. Direct labeling
The direct labeling method is a simple procedure in which the peptide is labeled in absence
of an exogenous chelator (Lupetti et al., 2003b). The direct approach is characterized by
poorly defined chemical structures, and it is generally thought that the 99mTc binds to the
sulfhydryl groups produced by reduction of the peptide disulfide bridge. Therefore, pepti‐
des containing cysteine seem to be a basic requirement for this labeling approach (Melen‐
dez-Alafort et al., 2009). The various complexes of 99mTc may be formed by interaction
between electron donor atoms and reduced technetium. In the case of antibiotics radiolabel‐
ing, in order to form bonds with technetium, the structure must contain electron donors
such as oxygen, nitrogen and sulfur. The labeled complex may be formed electron pairs of
these atoms with reduced technetium that is +1 or +3 in the reduced states similar to other
studies (Yurt Lambrechtet al., 2008b).The mechanism underlying the direct labeling method
is not fully elucidated, but it probably involves the reduction of 99mTc-pertechnetate by stan‐
nous ions and KBH4, the production of a TcO (pyrophosphate) intermediate, and the substi‐
tution reaction transferring the reduced technetium from this intermediate to the amino
groups of cationic peptides. The end-product from this reaction could be a reduced metal
(N4) complex, as reported for many tetrapeptides (Lupetti et al., 2003c).




Indirect method of labeling is used mostly for radiolabeling of peptides and it is not com‐
mon for antibiotics labeling. A widely used method for labeling of small peptides is by con‐
jugation of bifunctional chelators to the peptide and several attampts have been made using
hydrazinonicotinamid (HYNIC) and N3S compounds (S-benzoyl MAG3) (IAEA-TEC‐
DOC-1414, 2004). Among the various bifunctional chelating agents developed to date, HYN‐
IC constitutes a representative agent for 99mTc radiolabeling. Since HYNIC serves as a
monodentate or bidentate ligand, a coligand is necessary to complete the coordination
sphere of the technetium core. Tricine is often used as the coligand because of the produc‐
tion of 99mTc-HYNIC-labeled peptides and polypeptides with high radiochemical yields and
high specific activities in a short reaction time (Ono et al., 2001). Moreover, the indirect la‐
beling method permits post conjugation labeling, whereby the peptide is first conjugated to
the BFCA and then stored and labeled when required for clinical use. Furthermore, this ap‐
proach is the only choice for peptides containing disulfide bridges essential for receptor rec‐
ognition (Melendez-Alafort et al., 2009).
10. Conclusion
Nuclear medicine technology offers an attractive option for diagnosis of focal infections due
to its sensitivity based on pathophysiological and pathobiochemical processes. This ap‐
proach needs a reliable radiopharmaceutical that can concentrate in site of infection with
high specificity. As reviewed in this chapter, various conventional radiopharmaceuticals
which are basically on the uptake mechanism of targeting host inflammatory response are
not specific for infection imaging. In contrast, the use of radiopharmaceuticals for specific
targeting of microorganisms responsible for infection, have been proposed. In this respect,
radiolabeled antibiotics and antimicrobial peptides, by specific binding to the bacterial com‐
ponent, have the potential to distinguish microbial from non infectious inflammation at the
early stage of diseases. However, according to the irregular usage of antibiotics and increas‐
ing antibiotic-resistant microorganisms, it seems that antimicrobial peptides have more ad‐
vantages over antibiotics. We suggest that, antimicrobial peptides with wide promising
properties as the infection imaging agents have the ability to be used in clinical usages in
patients with suspected infections for more accurate diagnosis.
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